7Baggers

Intellia Therapeutics, Inc
(NASDAQ:NTLA) 

NTLA stock logo

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which i...

Founded: 2014
Full Time Employees: 270
CEO: John Leonard  
Sector: Healthcare
Industry: Biotechnology
PharmaceuticalsGene EditingGenomics
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 
                                             
      collaboration revenue
    		15,048,000 23,017,000 13,782,000 14,245,000 16,627,000 12,874,000 9,111,000 6,957,000 28,935,000 -1,917,000 11,992,000 13,594,000 12,606,000 13,573,000 13,266,000 14,030,000 11,252,000 12,854,000 7,204,000 6,550,000 6,445,000 6,595,000 22,220,000 16,263,000 12,916,000 10,936,000 10,616,000 11,118,000 10,433,000 7,880,000 7,408,000 7,677,000 7,469,000 6,668,000 7,317,000 5,917,000 6,215,000 5,627,000 4,869,000 4,206,000 1,777,000 
      yoy
    		-9.50% 78.79% 51.27% 104.76% -42.54% -771.57% -24.02% -48.82% 129.53% -114.12% -9.60% -3.11% 12.03% 5.59% 84.15% 114.20% 74.58% 94.91% -67.58% -59.72% -50.10% -39.69% 109.31% 46.28% 23.80% 38.78% 43.30% 44.82% 39.68% 18.18% 1.24% 29.74% 20.18% 18.50% 50.28% 40.68% 249.75%     
      qoq
    		-34.62% 67.01% -3.25% -14.33% 29.15% 41.30% 30.96% -75.96% -1609.39% -115.99% -11.78% 7.84% -7.12% 2.31% -5.45% 24.69% -12.46% 78.43% 9.98% 1.63% -2.27% -70.32% 36.63% 25.91% 18.11% 3.01% -4.52% 6.57% 32.40% 6.37% -3.50% 2.78% 12.01% -8.87% 23.66% -4.79% 10.45% 15.57% 15.76% 136.69%  
      operating expenses:
    		                                         
      research and development
    		80,737,000 88,652,000 94,747,000 97,035,000 108,427,000 116,877,000 123,380,000 114,207,000 111,847,000 108,981,000 113,696,000 115,276,000 97,116,000 100,034,000 96,651,000 90,199,000 133,095,000 71,161,000 60,486,000 58,884,000 39,276,000 38,231,000 39,756,000 37,771,000 34,650,000 31,731,000 27,513,000 25,460,000 23,709,000 19,918,000 23,237,000 23,467,000 22,493,000 21,170,000 17,481,000 15,565,000 13,431,000 11,331,000 7,861,000 7,423,000 5,225,000 
      general and administrative
    		34,843,000 33,075,000 30,512,000 27,206,000 29,007,000 32,444,000 30,501,000 31,793,000 31,091,000 28,994,000 29,403,000 30,652,000 27,448,000 23,626,000 22,145,000 22,132,000 22,403,000 22,108,000 18,711,000 16,683,000 13,594,000 10,763,000 10,566,000 11,526,000 11,314,000 8,976,000 8,431,000 13,118,000 10,533,000 8,708,000 8,270,000 7,805,000 7,406,000 10,213,000 5,711,000 6,369,000 5,732,000 5,118,000 4,705,000 3,729,000 3,246,000 
      total operating expenses
    		115,580,000 121,727,000 125,259,000 124,241,000 137,434,000 149,321,000 153,881,000 146,000,000 142,938,000 137,975,000 143,099,000 145,928,000 124,564,000 123,660,000 118,796,000 112,331,000 155,498,000 93,269,000 79,197,000 75,567,000 52,870,000 48,994,000 50,322,000 49,297,000 45,964,000 40,707,000 35,944,000 38,578,000 34,242,000 28,626,000 31,507,000 31,272,000 29,899,000 31,383,000 23,192,000 21,934,000 19,163,000 16,449,000 12,566,000 11,152,000 8,471,000 
      operating income
    		-100,532,000 -98,710,000 -111,477,000 -109,996,000 -120,807,000 -136,447,000 -144,770,000 -139,043,000 -114,003,000 -139,892,000 -131,107,000 -132,334,000 -111,958,000 -110,087,000 -105,530,000 -98,301,000 -144,246,000 -80,415,000 -71,993,000 -69,017,000 -46,425,000 -42,399,000 -28,102,000 -33,034,000 -33,048,000 -29,771,000 -25,328,000 -27,460,000 -23,809,000 -20,746,000 -24,099,000 -23,595,000 -22,430,000 -24,715,000 -15,875,000 -16,017,000 -12,948,000 -10,822,000 -7,697,000 -6,946,000 -6,694,000 
      yoy
    		-16.78% -27.66% -23.00% -20.89% 5.97% -2.46% 10.42% 5.07% 1.83% 27.07% 24.24% 34.62% -22.38% 36.90% 46.58% 42.43% 210.71% 89.66% 156.18% 108.93% 40.48% 42.42% 10.95% 20.30% 38.80% 43.50% 5.10% 16.38% 6.15% -16.06% 51.80% 47.31% 73.23% 128.38% 106.25% 130.59% 93.43%     
      qoq
    		1.85% -11.45% 1.35% -8.95% -11.46% -5.75% 4.12% 21.96% -18.51% 6.70% -0.93% 18.20% 1.70% 4.32% 7.35% -31.85% 79.38% 11.70% 4.31% 48.66% 9.50% 50.88% -14.93% -0.04% 11.01% 17.54% -7.76% 15.33% 14.76% -13.91% 2.14% 5.19% -9.25% 55.69% -0.89% 23.70% 19.65% 40.60% 10.81% 3.76%  
      operating margin %
    		-668.08% -428.86% -808.86% -772.17% -726.57% -1059.86% -1588.96% -1998.61% -394.00% 7297.44% -1093.29% -973.47% -888.13% -811.07% -795.49% -700.65% -1281.96% -625.60% -999.35% -1053.69% -720.33% -642.90% -126.47% -203.12% -255.87% -272.23% -238.58% -246.99% -228.21% -263.27% -325.31% -307.35% -300.31% -370.65% -216.96% -270.69% -208.33% -192.32% -158.08% -165.15% -376.70% 
      other income, net:
    		                                         
      interest income
    		5,205,000 6,476,000 6,714,000 7,402,000 8,603,000 10,631,000 12,122,000 12,422,000 12,632,000 12,459,000 12,740,000 12,653,000 11,980,000 5,354,000 1,945,000 703,000 540,000 503,000 349,000 211,000 220,000 207,000 262,000 641,000 1,242,000 1,495,000 1,694,000 1,777,000 1,869,000 1,680,000 1,397,000 1,376,000 1,074,000 752,000 519,000 424,000 317,000 259,000 215,000 46,000 5,000 
      change in fair value of investments
    		-904,000 -3,552,000 3,439,000 1,339,000 -2,125,000 -3,082,000 -3,064,000 -20,354,000 -6,065,000                                 
      total other income
    		4,301,000 2,924,000 10,153,000 8,741,000 6,478,000 7,549,000 9,058,000 -7,932,000 6,567,000 7,731,000 8,883,000 8,653,000 8,832,000 -3,320,000 -7,699,000 -2,377,000 -2,626,000                         
      net income
    		-96,231,000 -95,786,000 -101,324,000 -101,255,000 -114,329,000 -128,898,000 -135,712,000 -146,975,000 -107,436,000 -132,161,000 -122,224,000 -123,681,000 -103,126,000 -113,407,000 -113,229,000 -100,678,000 -146,872,000 -81,237,000 -71,644,000 -68,806,000 -46,205,000 -42,192,000 -27,840,000 -32,393,000 -31,806,000 -28,276,000 -23,634,000 -25,683,000 -21,940,000 -19,066,000 -22,702,000 -22,219,000 -21,356,000 -23,963,000 -15,356,000 -15,593,000 -12,631,000 -10,563,000 -7,482,000 -6,900,000 -6,689,000 
      yoy
    		-15.83% -25.69% -25.34% -31.11% 6.42% -2.47% 11.04% 18.83% 4.18% 16.54% 7.94% 22.85% -29.79% 39.60% 58.04% 46.32% 217.87% 92.54% 157.34% 112.41% 45.27% 49.21% 17.80% 26.13% 44.97% 48.31% 4.11% 15.59% 2.73% -20.44% 47.84% 42.49% 69.08% 126.86% 105.24% 125.99% 88.83%     
      qoq
    		0.46% -5.47% 0.07% -11.44% -11.30% -5.02% -7.66% 36.80% -18.71% 8.13% -1.18% 19.93% -9.07% 0.16% 12.47% -31.45% 80.79% 13.39% 4.12% 48.91% 9.51% 51.55% -14.06% 1.85% 12.48% 19.64% -7.98% 17.06% 15.07% -16.02% 2.17% 4.04% -10.88% 56.05% -1.52% 23.45% 19.58% 41.18% 8.43% 3.15%  
      net income margin %
    		-639.49% -416.15% -735.19% -710.81% -687.61% -1001.23% -1489.54% -2112.62% -371.30% 6894.16% -1019.21% -909.82% -818.07% -835.53% -853.53% -717.59% -1305.30% -632.00% -994.50% -1050.47% -716.91% -639.76% -125.29% -199.18% -246.25% -258.56% -222.63% -231.00% -210.29% -241.95% -306.45% -289.42% -285.93% -359.37% -209.87% -263.53% -203.23% -187.72% -153.67% -164.05% -376.42% 
      net income per share
    		-0.81 -0.82 -0.92 -0.98 -1.1 -1.26 -1.34 -1.52 -1.12 -1.46 -1.38 -1.4 -1.17 -1.38 -1.49 -1.33 -1.96 -1.1 -0.97 -1.01 -0.69 -0.7 -0.47 -0.61 -0.63 -0.58 -0.49 -0.56 -0.49 -0.43 -0.53 -0.52 -0.51 -0.63 -0.44 -0.45 -0.36 -0.26 -0.22 -0.36 -9.89 
      weighted-average shares outstanding, basic and diluted
    		118,490 108,376 110,188 103,732 103,500 98,849 101,002 96,975 95,502 88,770 88,645 88,185 87,772 76,972 76,047 75,823 74,751 70,894 73,706 68,164 67,183 55,987 58,754 53,369 50,491  48,554 45,814 45,234  43,161 42,836 42,043 36,006 35,189 34,916 34,723  34,316 19,121 676 
      other comprehensive loss:
    		                                         
      unrealized gain on marketable securities
    		-1,272 42 337 -404 452 -2,692 4,452 -208 -821 1,986 142 -1,482 2,989 -1,267.25 991      -13 -30 -124 -218 112 91 81 196 87             
      comprehensive loss
    		-97,503 -95,744 -100,987 -101,659 -113,877 -131,590 -131,260 -147,183 -108,257 -130,847 -121,928 -124,871 -98,343 -111,500 -113,043 -102,170 -152,302 -83,695 -71,805 -68,807 -46,218 -42,222 -27,964 -32,611 -31,694 -17,723.25 -23,553 -25,487 -21,853             
      other comprehensive gain:
    		                                         
      loss from equity method investment
    		         -4,728,000 -3,857,000 -4,000,000 -3,048,000 -3,248,000 -1,834,000 -3,252,000 -2,745,000                         
      change in fair value of contingent consideration
    		            -100,000 -5,426,000 -7,810,000 172,000 -421,000                         
      other comprehensive income:
    		                                         
      other comprehensive gain from equity method investment
    		         -672 154 292 1,794                             
      including the following revenue from related party
    		         159 1,946 5,792 4,935 5,522 4,414 7,767 5,384 69.25 277                       
      other comprehensive loss from equity method investment
    		             -1,525 -805 -560 -302                         
      unrealized loss on marketable securities
    		               -932 -5,128 -43.75 -161 -1                      
      income before income taxes
    		                                     -10,563,000 -7,482,000 -6,900,000 -6,689,000 
      income tax benefit
    		                                         
      net loss per common unit, basic and diluted
    		                                         
      weighted-average common units outstanding, basic and diluted
    		                                         
      benefit from income taxes
    		                                         
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 
                                               
        assets
      		                                         
        current assets:
      		                                         
        cash and cash equivalents
      		134,697,000 155,464,000 193,389,000 156,172,000 126,880,000 189,182,000 120,495,000 130,849,000 171,979,000 226,748,000 168,027,000 171,806,000 294,150,000 523,506,000 141,194,000 147,781,000 133,382,000 123,406,000 334,736,000 129,879,000 141,538,000 160,020,000 179,746,000 361,687,000 80,993,000 57,226,000 38,440,000 49,140,000 47,097,000 58,856,000 293,248,000 305,538,000 327,778,000 340,678,000 222,264,000 241,047,000 257,551,000 273,064,000 290,618,000 300,687,000 64,192,000 
        marketable securities
      		241,289,000 294,420,000 317,655,000 303,479,000 376,867,000 412,333,000 537,619,000 560,219,000 619,315,000 685,475,000 686,761,000 736,268,000 639,392,000 669,116,000 687,000,000 726,494,000 721,869,000 625,282,000 463,531,000 399,140,000 442,525,000 437,351,000 228,201,000 75,117,000 169,266,000 222,500,000   249,485,000 255,203,000            
        accounts receivable
      		9,131,000 9,468,000 11,050,000 11,353,000 10,504,000 8,517,000 8,854,000 12,329,000 36,427,000 36,456,000 6,491,000 5,056,000 4,906,000 3,768,000 4,023,000 2,854,000 1,801,000 2,031,000 2,491,000 1,993,000 953,000 2,130,000 1,217,000 3,864,000 13,368,000 4,620,000 3,599,000 4,188,000 3,591,000 7,547,000 2,813,000 8,609,000 7,466,000 10,471,000 4,493,000 2,764,000 2,443,000 6,454,000 1,112,000 1,000,000 1,000,000 
        prepaid expenses and other current assets
      		81,332,000 68,359,000 59,847,000 24,941,000 37,141,000 29,831,000 43,934,000 53,814,000 56,322,000 49,651,000 32,214,000 26,485,000 25,223,000 20,407,000 26,730,000 18,304,000 18,315,000 18,584,000 14,016,000 18,392,000 16,068,000 17,016,000 7,086,000 5,699,000 6,133,000 5,135,000 6,414,000 4,710,000 3,520,000 3,371,000 2,768,000 3,482,000 2,476,000 3,681,000 2,296,000 2,108,000 1,084,000 1,788,000 972,000 1,217,000 745,000 
        total current assets
      		466,449,000 527,711,000 581,941,000 495,945,000 551,392,000 639,863,000 710,902,000 757,211,000 884,043,000 998,330,000 893,493,000 939,615,000 963,671,000 1,216,797,000 858,947,000 895,433,000 875,367,000 769,303,000 814,774,000 549,404,000 601,084,000 616,517,000 416,250,000 446,367,000 269,760,000 289,481,000 295,935,000 307,137,000 303,693,000 324,977,000 298,829,000 317,629,000 337,720,000 354,830,000 229,053,000 245,919,000 261,078,000 281,306,000 292,702,000 302,904,000 65,937,000 
        marketable securities - noncurrent
      		141,261,000 155,250,000 158,814,000 170,855,000 203,353,000 260,215,000 286,567,000 248,805,000 162,090,000 99,864,000 137,752,000 164,013,000 225,038,000 69,338,000 20,533,000 32,604,000 139,486,000 337,361,000 350,451,000 22,262,000 16,735,000     4,746,000 9,868,000 4,739,000              
        property and equipment
      		15,516,000 17,671,000 20,421,000 22,806,000 25,123,000 27,381,000 28,763,000 30,273,000 32,075,000 32,760,000 33,800,000 33,194,000 31,606,000 27,921,000 26,597,000 25,868,000 23,697,000 20,968,000 19,946,000 18,530,000 16,157,000 15,943,000 15,612,000 16,402,000 17,251,000 17,996,000 17,206,000 16,694,000 16,669,000 17,061,000 16,935,000 16,580,000 16,010,000 15,272,000 13,560,000 12,578,000 11,418,000 10,628,000 5,492,000 4,421,000 4,228,000 
        operating lease right-of-use assets
      		97,543,000 105,955,000 117,883,000 129,045,000 137,979,000 219,292,000 100,331,000 105,412,000 110,424,000 115,375,000 118,775,000 123,550,000 128,265,000 133,076,000 101,290,000 73,775,000 76,473,000 79,143,000 81,788,000 77,070,000 77,912,000 39,114,000 22,210,000 23,469,000 24,918,000 19,137,000 20,663,000 20,923,000 21,012,000             
        investments and other assets
      		38,010,000 35,540,000 46,216,000 80,243,000 68,316,000 44,264,000 46,788,000 49,835,000 70,957,000 42,883,000 42,363,000 41,031,000 40,920,000 40,527,000 36,989,000 37,128,000 35,493,000 29,558,000                        
        total assets
      		758,779,000 842,127,000 925,275,000 898,894,000 986,163,000 1,191,015,000 1,173,351,000 1,191,536,000 1,259,589,000 1,300,977,000 1,243,349,000 1,323,240,000 1,417,889,000 1,520,114,000 1,084,458,000 1,110,424,000 1,202,788,000 1,294,464,000 1,334,961,000 672,243,000 716,891,000 676,322,000 458,555,000 490,830,000 314,752,000 334,280,000 346,635,000 352,441,000 344,363,000 347,315,000 321,233,000 339,778,000 359,545,000 376,235,000 249,170,000 264,975,000 279,263,000 298,969,000 301,469,000 310,624,000 75,540,000 
        liabilities and stockholders’ equity
      		                                         
        current liabilities:
      		                                         
        accounts payable
      		18,800,000 20,252,000 13,260,000 9,802,000 12,364,000 14,589,000 13,145,000 18,816,000 13,689,000 7,452,000 3,553,000 11,634,000 6,890,000 5,154,000 4,384,000 7,515,000 10,138,000 9,653,000 7,470,000 6,854,000 8,688,000 10,460,000 7,775,000 7,000 3,870,000 3,941,000 4,548,000 1,848,000 3,687,000 2,708,000 1,754,000 335,000 1,916,000 2,172,000 2,194,000 2,267,000 1,434,000 4,652,000 657,000 1,042,000 1,206,000 
        accrued expenses
      		37,920,000 49,862,000 40,841,000 41,553,000 40,805,000 55,355,000 51,206,000 45,127,000 43,276,000 67,017,000 57,979,000 49,534,000 44,822,000 60,876,000 58,379,000 44,871,000 42,876,000 43,309,000 24,633,000 37,150,000 21,215,000 25,554,000 19,348,000 15,374,000 13,102,000 13,273,000 11,644,000 11,898,000 7,735,000 10,742,000 9,893,000 9,156,000 6,605,000 7,999,000 5,939,000 5,312,000 3,559,000 5,900,000 4,810,000 4,288,000 2,973,000 
        current portion of operating lease liability
      		19,095,000 26,480,000 27,378,000 26,990,000 38,763,000 20,246,000 19,177,000 18,963,000 18,763,000 18,599,000 17,074,000 16,750,000 16,328,000 16,685,000 13,551,000 9,568,000 9,338,000 9,112,000 8,705,000 7,415,000 8,255,000 5,696,000 6,198,000 5,834,000 5,693,000 5,745,000                
        current portion of deferred revenue
      		630,000 7,290,000 12,247,000 17,154,000 20,661,000 20,661,000 22,155,000 22,184,000 22,184,000 22,140,000 13,347,000 21,933,000 35,343,000 43,839,000 54,818,000 61,806,000 63,759,000 63,759,000 56,759,000 22,544,000 22,544,000 22,544,000 22,544,000 37,927,000 12,639,000 12,674,000 15,822,000 19,652,000 23,431,000 27,122,000 14,268,000 15,678,000 17,062,000 21,188,000 17,653,000 18,792,000 19,917,000 20,178,000 17,166,000 16,287,000 6,781,000 
        total current liabilities
      		76,445,000 103,884,000 93,726,000 95,499,000 112,593,000 110,851,000 105,683,000 105,090,000 97,912,000 115,208,000 91,953,000 99,851,000 103,383,000 126,554,000 131,132,000 123,760,000 126,111,000 125,833,000 97,567,000 73,963,000 60,702,000 64,254,000 55,865,000 59,142,000 35,304,000 35,633,000 37,519,000 38,463,000 39,234,000 40,572,000 25,915,000 25,169,000 25,583,000 31,359,000 25,786,000 26,371,000 24,910,000 30,730,000 22,633,000 21,617,000 10,960,000 
        long-term operating lease liability
      		61,395,000 66,849,000 70,588,000 75,601,000 80,490,000 189,952,000 82,446,000 87,332,000 92,100,000 96,747,000 101,263,000 105,582,000 109,801,000 114,018,000 84,097,000 59,997,000 62,480,000 64,911,000 67,273,000 63,259,000 64,487,000 33,609,000 16,000,000 17,349,000 18,669,000 12,630,000                
        total liabilities
      		137,840,000 170,733,000 176,853,000 183,639,000 206,244,000 319,059,000 210,736,000 220,474,000 223,452,000 250,808,000 205,935,000                               
        commitments and contingencies
      		                                         
        stockholders’ equity:
      		                                         
        common stock, 0.0001 par value...
      		12,000 12,000 12,000 10,000 10,000 10,000 10,000 10,000 10,000 9,000 9,000 9,000 9,000 9,000 8,000 8,000 8,000 7,000 7,000 7,000 7,000 7,000 6,000 6,000 5,000 5,000 5,000 5,000 5,000 5,000 4,000 4,000 4,000 4,000 4,000 4,000 4,000 4,000 4,000 4,000  
        additional paid-in capital
      		3,307,492,000 3,260,444,000 3,241,728,000 3,107,576,000 3,070,581,000 3,048,741,000 3,007,810,000 2,884,997,000 2,802,889,000 2,710,797,000 2,567,195,000 2,512,741,000 2,473,825,000 2,420,223,000 1,898,091,000 1,840,644,000 1,811,681,000 1,745,870,000 1,729,029,000 1,044,939,000 1,027,192,000 962,173,000 722,500,000 716,503,000 580,065,000 570,493,000 547,913,000 525,574,000 487,559,000 478,968,000 445,225,000 438,589,000 432,533,000 421,706,000 272,993,000 269,375,000 266,080,000 263,403,000 261,127,000 259,123,000 1,483,000 
        accumulated other comprehensive income
      		-240,000 1,032,000 990,000 653,000 1,057,000 605,000 3,297,000           -2,632,000 -174,000 -13,000 -12,000 1,000 31,000 155,000 373,000 261,000 336,000 255,000 59,000             
        accumulated deficit
      		-2,686,325,000 -2,590,094,000 -2,494,308,000 -2,392,984,000 -2,291,729,000 -2,177,400,000 -2,048,502,000 -1,912,790,000 -1,765,815,000 -1,658,379,000 -1,526,218,000 -1,403,994,000 -1,280,313,000 -1,177,187,000 -1,063,780,000 -950,551,000 -849,873,000 -703,001,000 -621,764,000 -550,120,000 -481,314,000 -435,109,000 -392,917,000 -365,077,000 -332,684,000 -300,878,000 -272,602,000 -248,968,000 -223,285,000 -201,025,000 -181,959,000 -159,257,000 -137,038,000 -121,113,000 -97,150,000 -81,794,000 -66,201,000 -53,570,000 -43,007,000 -35,525,000 -28,625,000 
        total stockholders’ equity
      		620,939,000 671,394,000 748,422,000 715,255,000 779,919,000 871,956,000 962,615,000 971,062,000 1,036,137,000 1,050,169,000 1,037,414,000 1,104,888,000 1,190,843,000 1,235,584,000 824,951,000 880,547,000 953,754,000 1,040,244,000 1,107,098,000 494,813,000 545,873,000 527,072,000 329,620,000 351,587,000 247,759,000 269,881,000 275,652,000 276,866,000 264,338,000 277,920,000    300,597,000   199,883,000 209,837,000 218,124,000 223,602,000  
        total liabilities and stockholders’ equity
      		758,779,000 842,127,000 925,275,000 898,894,000 986,163,000 1,191,015,000 1,173,351,000 1,191,536,000 1,259,589,000 1,300,977,000 1,243,349,000 1,323,240,000 1,417,889,000 1,520,114,000 1,084,458,000 1,110,424,000 1,202,788,000 1,294,464,000 1,334,961,000 672,243,000 716,891,000 676,322,000 458,555,000 490,830,000 314,752,000 334,280,000 346,635,000 352,441,000 344,363,000 347,315,000    376,235,000   279,263,000 298,969,000 301,469,000 310,624,000  
        deferred revenue, net of current portion
      		  12,539,000 12,539,000 13,161,000 18,256,000 22,607,000 28,052,000 33,440,000 38,853,000 12,719,000 12,919,000 13,862,000 19,932,000 25,678,000 35,330,000 49,481,000 63,476,000 63,023,000 40,208,000 45,829,000 51,387,000 57,070,000 62,752,000 13,020,000 16,136,000 19,322,000 22,508,000 25,659,000 28,810,000 31,996,000 35,181,000 38,332,000 44,111,000 47,336,000 50,785,000 54,092,000 58,109,000 60,406,000 65,042,000 2,753,000 
        equity method investment
      		         11,765,000 17,166,000 21,837,000 28,389,000 32,455,000 40,102,000 45,616,000 52,272,000 58,131,000 62,837,000                       
        accumulated other comprehensive loss
      		       -1,155,000 -947,000 -2,258,000 -3,572,000 -3,868,000 -2,678,000 -7,461,000 -9,368,000 -9,554,000 -8,062,000             -28,000            
        contingent consideration liability
      		             24,026,000 18,600,000                           
        other long-term liabilities
      		               10,790,000 10,962,000             13,000 52,000 92,000 131,000 168,000 201,000 234,000 378,000 293,000 306,000 363,000 349,000 
        other assets
      		                  5,165,000 4,977,000 5,003,000 4,748,000 4,483,000 4,592,000 2,823,000 2,920,000 2,963,000 2,948,000 2,989,000 5,277,000 5,469,000 5,569,000 5,815,000 6,133,000 6,557,000 6,478,000 6,767,000 7,035,000 3,275,000 3,299,000 5,375,000 
        marketable securities - current
      		                          247,482,000 221,959,000              
        current portion of lease liability
      		                          5,505,000 5,065,000 4,381,000             
        long-term lease liability
      		                          14,142,000 14,604,000 15,132,000             
        proceeds due from at-the-market offerings
      		                           27,140,000              
        liabilities and stockholders' equity
      		                                         
        stockholders' equity:
      		                                         
        total stockholders' equity
      		                              263,270,000 279,336,000 295,499,000  175,847,000 187,585,000      
        total liabilities and stockholders' equity
      		                              321,233,000 339,778,000 359,545,000  249,170,000 264,975,000      
        convertible preferred stock, 0.0001 par value...
      		                                         
        stockholders’ equity
      		                                         
        convertible preferred stock (series b, series a-2, series a-1, junior and founder), 0.0001 par value...
      		                                        88,620,000 
        liabilities and stockholders’ deficit
      		                                         
        stockholders’ deficit:
      		                                         
        total stockholders’ deficit
      		                                        -27,142,000 
        total liabilities and stockholders’ deficit
      		                                        75,540,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 
                                                 
          cash flows from operating activities:
        		                                         
          net loss
        		-96,231,000 -95,786,000 -101,324,000 -101,255,000 -114,329,000 -128,898,000 -135,712,000 -146,975,000 -107,436,000 -132,161,000 -122,224,000 -123,681,000 -103,126,000 -113,407,000 -113,229,000 -100,678,000 -146,872,000 -81,237,000 -71,644,000 -68,806,000 -46,205,000 -42,192,000 -27,840,000 -32,393,000 -31,806,000 -28,276,000 -23,634,000 -25,683,000 -21,940,000 -19,066,000 -22,702,000 -22,219,000 -21,356,000 -23,963,000 -15,356,000 -15,593,000 -12,631,000 -10,563,000 -7,482,000 -6,900,000 -6,689,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                         
          depreciation and amortization
        		2,202,000 2,380,000 2,415,000 2,474,000 2,498,000 2,566,000 2,608,000 2,599,000 2,512,000 2,466,000 2,290,000 2,170,000 2,050,000 2,031,000 1,950,000 1,837,000 1,754,000 1,880,000 1,786,000 1,634,000 1,591,000 1,602,000 1,602,000 1,566,000 1,541,000 1,583,000 1,383,000 1,322,000 1,299,000 1,227,000 1,152,000 1,073,000 1,012,000 833,000 790,000 711,000 660,000 405,000 265,000 247,000 187,000 
          stock-based compensation
        		13,479,000 16,739,000 19,604,000 22,036,000 21,840,000 39,617,000 39,619,000 40,861,000 34,176,000                                 
          accretion of investment discounts
        		-535,000  -1,085,000 -1,667,000 -2,280,000                  73,000 -68,000 -200,000 -428,000 -667,000 -1,208,000 -1,422,000             
          change in fair value of investments
        		904,000 3,552,000 -3,439,000 -1,339,000 2,125,000 3,082,000 3,064,000 20,354,000 6,065,000                                 
          changes in operating assets and liabilities:
        		                                         
          accounts receivable
        		337,000 1,582,000 303,000 -849,000 -1,987,000 337,000 3,474,000 24,099,000 29,000 -29,965,000 -1,434,000 -151,000 -1,138,000 255,000 -1,168,000 -1,054,000 230,000 460,000 -498,000 -1,040,000 1,177,000 -913,000 2,647,000 9,504,000 -8,748,000 -1,021,000 589,000 -597,000 3,956,000 -4,734,000 5,796,000 -1,143,000 3,005,000 -5,978,000 -1,729,000 -321,000 4,011,000 -5,342,000    
          prepaid expenses and other current assets
        		-12,972,000 -8,690,000 -23,035,000 5,155,000 218,000 541,000 10,882,000 2,507,000 -8,746,000 -15,362,000 -5,728,000 -1,263,000 -4,815,000 -1,932,000 -662,000 12,000 422,000 -4,725,000 3,630,000 -3,255,000 -5,448,000 -7,255,000 -1,387,000 -116,000 -448,000 1,280,000 -1,704,000 -1,189,000 -150,000 -603,000 714,000 -1,006,000 1,205,000 -1,385,000 -188,000 -1,024,000 704,000 -817,000 245,000 -472,000 65,000 
          operating lease right-of-use assets
        		8,411,000 8,294,000 8,641,000 8,933,000 7,218,000 6,422,000 5,081,000 5,012,000 4,951,000 4,863,000 4,775,000 4,715,000 4,658,000 4,605,000 3,148,000 2,697,000 2,671,000                         
          other assets
        		-74,000 1,938,000 25,288,000 -10,589,000 -13,826,000 -559,000 -17,000 769,000 724,000 129,000 -333,000 -110,000 -393,000 -109,000 -180,000 116,000 -918,000 365,000 -19,000 26,000 -255,000 -265,000 109,000 142,000 97,000 43,000 -15,000 41,000 84,000 358,000 100,000 246,000 318,000 424,000 -79,000 289,000 268,000 -3,760,000 24,000 124,000 -2,823,000 
          accounts payable
        		-1,420,000 6,959,000 3,459,000 -2,562,000 -1,869,000 1,436,000 -5,552,000 5,347,000 5,569,000 3,941,000 -7,706,000 5,117,000 1,170,000 750,000 -1,624,000 -3,653,000 -57,000 2,399,000 736,000 -1,689,000 -917,000 1,615,000 7,344,000 -3,529,000 -370,000 -30,000 2,203,000 -1,649,000 1,356,000 297,000 1,534,000 -1,658,000 59,000 -256,000 438,000 284,000 -954,000 1,630,000 521,000 -280,000 -87,000 
          accrued expenses
        		-11,947,000 9,027,000 -715,000 832,000 -14,415,000 3,953,000 6,219,000 1,848,000 -22,403,000 9,032,000 9,517,000 4,867,000 -17,392,000 3,072,000 13,573,000 2,996,000 -3,717,000 18,430,000 -11,305,000 14,723,000 -4,588,000 6,312,000 4,285,000 2,257,000 177,000 1,267,000 96,000 3,552,000 -2,605,000 1,357,000 1,118,000 1,914,000 -1,609,000 2,092,000 554,000 1,641,000 -1,893,000 1,309,000 688,000 1,187,000 -134,000 
          deferred revenue
        		-6,660,000 -13,980,000 -4,907,000 -4,129,000 -5,095,000 -5,845,000 -5,474,000 -5,389,000 -5,368,000 34,927,000 -8,786,000 -14,353,000 -14,566,000 -16,725,000 -16,640,000 -16,104,000 -13,995,000 -14,369,000 -5,807,000 -5,621,000 -5,558,000 -5,683,000 -21,065,000 75,020,000 -3,151,000 -6,334,000 -7,016,000 -6,930,000 -6,842,000 9,668,000 -4,595,000 -4,535,000 -4,474,000 310,000 -4,588,000 -4,432,000 -4,278,000 715,000 -3,757,000 71,795,000 -778,000 
          operating lease liabilities
        		-12,840,000 -4,636,000 -4,625,000 -16,662,000 -29,028,000 -4,245,000 -4,672,000 -4,569,000 -4,483,000 -4,455,000 -3,996,000 -3,797,000 -4,420,000 -3,335,000 -2,089,000 -2,254,000 -2,204,000 -1,899,000 -2,156,000 -3,648,000 -1,402,000 -1,388,000 -1,397,000 -1,359,000 -1,360,000 -3,826,000                
          net cash from operating activities
        		-117,346,000 -69,285,000 -76,899,000 -99,622,000 -148,930,000 -85,195,000 -84,837,000 -58,186,000 -120,662,000 -93,054,000 -101,381,000 -90,323,000 -109,328,000 -89,869,000 -78,526,000 -85,091,000 -79,801,000 -54,651,000 -65,022,000 -52,981,000 -52,376,000 -40,226,000 -28,558,000 57,417,000 -38,545,000 -28,662,000 -25,448,000 -27,677,000 -21,453,000 -8,538,000 -12,454,000 -22,495,000 -17,770,000 -21,306,000 -16,894,000 -15,678,000 -11,398,000 -14,410,000 -7,610,000 67,550,000 -9,421,000 
          capital expenditures
        		-79,000 -126,000 -29,000 -239,000 -653,000 -778,000 -1,536,000 -1,228,000 -1,659,000 -1,547,000 -5,778,000 -4,828,000 -307,000 -4,469,000 -5,807,000 -3,951,000 2,292,000 -2,834,000 -5,874,000 -1,870,000 -1,511,000 -43,000 -585,000 -1,354,000 -95,000 -2,788,000 -1,599,000 -520,000 -1,087,000 -1,443,000 -2,511,000 -186,000 -1,147,000 -2,193,000 -2,699,000 -610,000 -3,784,000 -1,259,000 126,000 -1,852,000 -90,000 
          free cash flows
        		-117,425,000 -69,411,000 -76,928,000 -99,861,000 -149,583,000 -85,973,000 -86,373,000 -59,414,000 -122,321,000 -94,601,000 -107,159,000 -95,151,000 -109,635,000 -94,338,000 -84,333,000 -89,042,000 -77,509,000 -57,485,000 -70,896,000 -54,851,000 -53,887,000 -40,269,000 -29,143,000 56,063,000 -38,640,000 -31,450,000 -27,047,000 -28,197,000 -22,540,000 -9,981,000 -14,965,000 -22,681,000 -18,917,000 -23,499,000 -19,593,000 -16,288,000 -15,182,000 -15,669,000 -7,484,000 65,698,000 -9,511,000 
          cash flows from investing activities:
        		                                         
          purchases of property and equipment
        		-79,000 -126,000 -29,000 -239,000 -735,000 -981,000 -1,279,000 -1,012,000 -2,506,000 -1,520,000 -4,332,000 -4,301,000 -3,832,000 -3,912,000 -4,237,000 -3,980,000 -1,429,000 -2,868,000 -4,538,000 -2,938,000 -2,412,000 -1,006,000 -698,000 -1,036,000 -845,000 -2,572,000 -1,748,000 -941,000 -1,533,000 -1,592,000 -2,016,000 -900,000 -1,850,000 -2,397,000 -2,260,000 -1,272,000 -4,162,000 -3,405,000 -605,000 -1,147,000 -1,008,000 
          purchases of marketable securities
        		-46,965,000 -67,050,000 -116,651,000 -55,600,000 -83,209,000 -169,102,000 -206,103,000 -300,810,000 -259,558,000 -149,775,000 -129,370,000 -243,286,000 -382,033,000 -236,434,000 -161,074,000   -247,861,000 -587,328,000 -37,101,000 -148,330,000 -228,912,000 -213,582,000 -1,000 -31,207,000 -33,044,000 -81,404,000 -163,310,000 -19,272,000             
          sales and maturities of marketable securities
        		113,354,000 94,710,000 115,939,000 162,749,000 178,272,000 321,648,000 199,673,000                                   
          net cash from investing activities
        		66,310,000 27,534,000 -741,000 106,910,000 94,328,000 151,565,000 -7,709,000 -24,190,000 5,901,000 45,939,000 79,500,000 -34,538,000 -122,248,000 -30,152,000 47,643,000 95,345,000 47,473,000 -159,115,000 -399,381,000 33,260,000 -25,542,000 -210,918,000 -153,980,000 92,963,000 57,448,000 27,884,000 -31,652,000 23,249,000 5,695,000 -256,016,000 -2,016,000 -900,000 -1,850,000 -2,397,000 -2,260,000 -1,272,000 -4,162,000 -3,405,000 -605,000 -1,147,000 -1,008,000 
          cash flows from financing activities:
        		                                         
          net proceeds from issuance of common stock through at-the-market offerings
        		33,569,000 0 114,760,000   -30,000 80,497,000 38,398,000 58,034,000                                 
          net cash from financing activities
        		33,569,000 1,977,000 114,857,000   2,317,000 82,192,000 41,246,000 59,992,000 106,484,000 19,102,000 2,516,000 2,221,000 505,763,000 23,977,000 5,895,000 47,320,000 2,280,000 668,680,000 7,133,000 58,595,000 234,093,000 597,000 132,225,000 4,864,000 19,564,000 46,400,000 6,471,000 3,999,000 30,162,000 2,180,000 1,155,000 6,720,000 142,117,000 371,000 446,000 47,000 261,000 -1,854,000 170,092,000 -1,195,000 
          net decrease in cash, cash equivalents and restricted cash equivalents
        		-17,467,000   21,940,000 -54,602,000  -10,354,000 -41,130,000 -54,769,000                                 
          cash, cash equivalents and restricted cash equivalents, beginning of period
        		167,568,000 0 0 0 202,787,000 0 0 0 240,353,000 0 0                               
          cash, cash equivalents and restricted cash equivalents, end of period
        		150,101,000 -39,774,000 37,217,000 21,940,000 148,185,000 68,687,000 -10,354,000 -41,130,000 185,584,000 59,369,000 -2,779,000                               
          reconciliation of cash, cash equivalents and restricted cash equivalents to condensed consolidated balance sheet:
        		                                         
          cash and cash equivalents
        		134,697,000 -37,925,000 37,217,000 29,292,000 126,880,000 68,687,000 -10,354,000 -41,130,000 171,979,000 58,721,000 -3,779,000 -122,344,000 294,150,000 382,312,000 -6,587,000 14,399,000 133,382,000 -211,330,000 204,857,000 -11,659,000 141,538,000 -19,726,000 -181,941,000                   
          restricted cash equivalents, included in prepaid expenses and other current assets, and investments and other assets
        		15,404,000  0 -7,352,000 21,305,000                                     
          total cash, cash equivalents and restricted cash equivalents
        		150,101,000 -39,774,000 37,217,000 21,940,000 148,185,000 68,687,000 -10,354,000 -41,130,000 185,584,000 59,369,000 -2,779,000           -17,051,000 -181,941,000                   
          supplemental disclosures of cash flow information:
        		                                         
          purchases of property and equipment unpaid at period end
        		    82,000 203,000 -257,000 -216,000 847,000 -27,000 -1,446,000 -527,000 3,525,000 -557,000 -1,570,000 29,000 3,721,000 34,000 -1,336,000 1,068,000 901,000 963,000 113,000 -318,000 750,000 -216,000 149,000 421,000 446,000 149,000 -495,000 714,000 703,000 204,000 -439,000 662,000 378,000 2,146,000 731,000 -705,000 918,000 
          reduction of right-of-use assets from remeasurement of lease liabilities
        		 0 0 0 61,917,000                                     
          loss on disposal of property and equipment
        		     0    67,000 -10,000               -16,000 0 16,000 1,000 91,000 13,000   54,000 50,000   11,000 0   
          accelerated amortization/impairment of right-of-use assets
        		                                         
          accretion of investment discounts and premiums
        		      -4,281,000 -4,649,000 -5,285,000                                 
          (recognition) deferral of equity method investment intra-entity profit on sales
        		     0 0 0 -20,967,000                                 
          loss from equity method investment
        		         4,728,000 3,857,000 4,000,000 3,048,000 3,248,000 1,834,000 3,252,000 2,745,000                         
          change in fair value of contingent consideration
        		         0 0 0 100,000 5,426,000 7,810,000 -172,000 421,000                         
          proceeds from options exercised
        		 625,000    1,030,000 1,695,000 1,179,000 1,958,000 995,000 4,384,000 465,000 755,000 533,000 722,000 4,827,000 8,435,000 1,226,000 20,365,000 6,163,000 13,340,000 9,607,000 597,000 1,034,000 336,000 870,000 192,000 1,664,000 360,000 1,195,000 2,180,000 557,000 6,720,000 648,000 371,000 90,000 47,000     
          issuance of shares through employee stock purchase plan
        		 1,352,000 0   1,317,000 0   1,878,000 0   1,581,000 0   1,054,000 0   872,000 0   558,000 0   420,000 0   469,000 0       
          reconciliation of cash, cash equivalents and restricted cash equivalents to consolidated balance sheet:
        		                                         
          restricted cash equivalents, included in investments and other assets
        		     0 0 0 13,605,000 648,000 1,000,000 -1,000 11,958,000 3,430,000 -319,000 1,750,000 7,096,000                         
          operating lease liability arising from obtaining right-of-use assets
        		                                         
          non-cash trade-in of property and equipment
        		     0        0                            
          proceeds from at-the-market offerings unpaid at period end
        		                        551,000                 
          shares issued for rewrite contingent consideration
        		         0                                
          gain on disposal of property and equipment
        		                                         
          accelerated amortization of right-of-use asset
        		                                         
          recognition of equity method investment intra-entity profit on sales
        		                                         
          net increase in cash, cash equivalents and restricted cash equivalents
        		          -2,779,000                               
          proceeds from option exercises unpaid at period end
        		                                         
          amortization of investment discounts and premiums
        		         -6,307,000 -7,923,000                               
          in-process research and development expense
        		                                         
          proceeds from sale of property and equipment
        		             0                            
          acquired in-process research and development, net of cash acquired of 287
        		             0 0 0 -44,832,000                         
          net proceeds from issuance of common stock through follow-on offerings, net of issuance costs
        		                                         
          contingent consideration liability assumed in asset acquisition
        		             0 0 0 10,541,000                         
          maturities of marketable securities
        		        267,965,000 197,234,000 213,202,000 213,049,000 263,617,000 210,194,000 212,804,000 130,849,000 93,734,000 94,614,000 192,485,000 73,299,000 125,200,000 19,000,000 60,300,000 94,000,000 89,500,000 63,500,000 51,500,000 187,500,000 26,500,000             
          deferral of equity method investment intra-entity profit on sales
        		         0 968,000 2,844,000 2,812,000 2,875,000 2,874,000 2,844,000 2,812,000                         
          investment in kyverna therapeutics, inc.
        		                                         
          net proceeds from issuance of common stock through at-the-market offerings, net of issuance costs
        		                                         
          net increase in cash and cash equivalents and restricted cash equivalents
        		            -229,355,000 385,742,000 -6,906,000 16,149,000 14,992,000      -181,941,000                   
          right-of-use assets acquired under operating leases
        		                 -57,000 7,461,000 1,580,000 40,394,000 18,493,000 412,000 180,000 7,347,000 0 1,211,000               
          non-cash contribution of intellectual property to avencell therapeutics, inc.
        		                                         
          non-cash contribution of intellectual property to sparingvision sas
        		                                         
          non-cash contribution of intellectual property to kyverna therapeutics, inc.
        		                                         
          the accompanying notes are an integral part of these consolidated financial statements.
        		                                         
          equity-based compensation
        		          35,352,000 36,400,000 27,255,000 24,626,000 25,215,000 23,068,000 18,491,000 14,561,000 15,410,000 10,614,000 6,424,000 5,582,000 5,400,000 4,764,000 4,157,000 3,016,000 3,079,000 4,404,000 4,592,000 3,582,000 4,456,000 4,901,000 4,107,000 6,596,000 3,247,000 2,849,000 2,630,000 2,015,000 2,055,000 1,833,000 812,000 
          right-of-use asset acquired under operating lease
        		                                         
          in-process research and development charge
        		             0 0 0 55,990,000                         
          proceeds from issuance of common stock through at-the-market offerings, net of issuance costs
        		           0 1,466,000 165,757,000 23,255,000 0 38,885,000 0 0 0 45,255,000                     
          shares issued for rewrite research milestone liability
        		           0 24,126,000                             
          amortization of investment premiums
        		            -4,571,000 -1,249,000 824,000 2,002,000 2,426,000 2,634,000 2,102,000                       
          cash and cash equivalents and restricted cash equivalents, beginning of period
        		            535,463,000 0 0 0 125,486,000      0                   
          cash and cash equivalents and restricted cash equivalents, end of period
        		            306,108,000 385,742,000 -6,906,000 16,149,000 140,478,000      -181,941,000                   
          reconciliation of cash and cash equivalents and restricted cash equivalents to condensed consolidated balance sheet:
        		                                         
          total cash and cash equivalents and restricted cash equivalents
        		            306,108,000 385,742,000 -6,906,000 16,149,000 140,478,000                         
          proceeds from issuance of common stock through follow-on offerings, net of issuance costs
        		                 0                        
          proceeds from issuance of common stock to regeneron pharmaceuticals, inc.
        		                                         
          reconciliation of cash and cash equivalents and restricted cash equivalents to consolidated balance sheet:
        		                                         
          see notes to consolidated financial statements.
        		                                         
          offering costs unpaid at period end
        		                                         
          operating right-of-use assets
        		                  2,743,000 2,422,000 1,596,000 1,591,000 1,671,000 1,629,000 1,566,000 4,080,000                
          proceeds from issuance of common stock to regeneron
        		                     0 0                   
          net increase in cash and cash equivalents and restricted cash and cash equivalents
        		                  204,277,000 -12,588,000 -19,323,000                     
          cash and cash equivalents and restricted cash and cash equivalents, beginning of period
        		                  0 0 164,606,000                     
          cash and cash equivalents and restricted cash and cash equivalents, end of period
        		                  204,277,000 -12,588,000 145,283,000                     
          reconciliation of cash and cash equivalents and restricted cash and cash equivalents to condensed consolidated balance sheet:
        		                                         
          restricted cash and cash equivalents, included in prepaids and other current assets and other assets
        		                  -580,000 -929,000 3,745,000                     
          total cash and cash equivalents and restricted cash and cash equivalents
        		                  204,277,000 -12,588,000 145,283,000                     
          non-cash contribution of intellectual property to newco
        		                                         
          amortization/accretion of investment premiums/discounts
        		                    1,209,000                     
          accretion of investment premiums
        		                                         
          other long-term liabilities
        		                             -39,000 -40,000 -39,000 -37,000 -33,000 -33,000 -144,000 85,000 -13,000 -57,000 14,000 26,000 
          proceeds from issuance of common stock through follow-on offerings, net of issuance costs of 0.7 million
        		                                         
          proceeds from issuance of common stock through at-the-market offerings, net of issuance costs of 0.2 million
        		                                         
          restricted cash equivalents, included in prepaids and other current assets and other assets
        		                                         
          proceeds from issuance of common stock through follow-on offering, net of issuance costs of 0.4 million
        		                      0                   
          proceeds from issuance of common stock through at-the-market offerings, net of issuance costs of 0.1 million and 0.3 million, respectively
        		                                         
          restricted cash equivalents, included in other assets
        		                      0                   
          proceeds from issuance of common stock through at-the-market offerings, net of issuance costs of 0.1 million
        		                                         
          proceeds from common stock offerings, net of offering costs
        		                        4,528,000 18,136,000 46,208,000               
          net increase in cash and cash equivalents
        		                        23,767,000         118,414,000 -18,783,000   -17,554,000 -10,069,000 236,495,000 -11,624,000 
          cash and cash equivalents, beginning of period
        		                        57,226,000 0 0 0 58,856,000 0 0 0 340,678,000 0 0 0 273,064,000 0 0 0 75,816,000 
          cash and cash equivalents, end of period
        		                        80,993,000 18,786,000 -10,700,000 2,043,000 47,097,000 -234,392,000 -12,290,000 -22,240,000 327,778,000 118,414,000 -18,783,000 -16,504,000 257,551,000 -17,554,000 -10,069,000 236,495,000 64,192,000 
          net decrease in cash and cash equivalents
        		                          -10,700,000 2,043,000 -11,759,000  -12,290,000 -22,240,000 -12,900,000    -15,513,000     
          non-cash lease expense
        		                           244,000 218,000             
          proceeds from common stock offering, net of offering costs
        		                            3,639,000             
          adjustments to reconcile net loss to net cash (used in) provided by operating activities:
        		                                         
          payments to acquire in-process research and development
        		                                     0 -200,000 -200,000 -200,000 
          payment of preferred unit and preferred stock issuance costs
        		                                     0 0 0 -100,000 
          proceeds from common stock offering
        		                                     0 0   
          payment of common stock offering costs
        		                                     0 -1,654,000   
          conversion of convertible preferred stock to common stock
        		                                         
          proceeds from sale of class a-1 and a-2 preferred units and series b preferred stock
        		                                         
          acquisition of in-process research and development unpaid at period end
        		                                       -200,000 400,000 
          financing costs incurred but unpaid at period end
        		                                       1,150,000 454,000 
          acquired in-process research and development
        		                                         
          benefit from intraperiod tax allocation
        		                                         
          acquisition of in-process research and development
        		                                         
          proceeds from sale of common units
        		                                         
          noncash portion of acquired in-process research and development
        		                                         
          proceeds from sale of class a-2 preferred units and series b preferred stock
        		                                         
          proceeds from sale of class a-2 preferred units
        		                                         
          payment of proposed public offering costs
        		                                        -895,000